Autonomic Testing / Sudomotor Tests — CPB 0485 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0485 governing autonomic testing coverage, effective September 26, 2025. Here's what billing teams need to know before claims go out the door.

Aetna's updated autonomic testing coverage policy now explicitly covers CPT codes 95921, 95922, 95923, and 95924 across 11 qualifying conditions — including Long-COVID syndrome with suspected autonomic disorder, which is a meaningful addition. The CPB 0485 Aetna system update expands the list of covered indications and gives billing teams cleaner, more specific medical necessity criteria to document against. If your practice bills autonomic testing for neurology, endocrinology, or rheumatology patients, this update affects your charge capture and your ICD-10 pairing strategy starting September 26, 2025.

Quick-Reference Table

Aetna Autonomic Testing Coverage Criteria and Medical Necessity Requirements 2025

The core of this Aetna autonomic testing coverage policy is a 11-condition list. If your patient doesn't have one of these documented diagnoses, Aetna will not cover the test. That's the first filter your billing team needs to apply before CPT 95921, 95922, 95923, or 95924 ever hits a claim.

Aetna considers autonomic testing medically necessary as a diagnostic tool for any of the following:

Long-COVID with suspected autonomic disorder is the standout addition here. Post-COVID dysautonomia has been a documentation gray area for billing teams since 2021. Aetna is now giving it an explicit covered indication — that matters for reimbursement.

The medical necessity bar is tied directly to diagnostic intent. These tests — including quantitative sudomotor axon reflex test (QSART), silastic sweat imprint, and thermoregulatory sweat test (TST) — must be used as a diagnostic tool, not for monitoring or screening purposes. Your documentation needs to reflect that clinical intent clearly.

Aetna's autonomic testing billing guidelines don't spell out a prior authorization requirement within the coverage policy itself. That doesn't mean prior authorization isn't required under your specific plan contracts — it means you need to verify at the plan level before scheduling. Call to confirm on any Aetna commercial or managed Medicaid product before the test runs.

Coverage Indications at a Glance

Aetna Autonomic Testing Billing Guidelines and Action Items 2025

Here's what your billing team should do before September 26, 2025, and immediately after:

1. Audit open and pending claims for CPT 95921–95924.
Pull every claim from the past 90 days that includes these codes. Check whether the linked ICD-10 diagnosis matches one of the 11 covered indications. If you've been using a broader or less specific code, now is the time to correct it — not after the denial comes back.

2. Update your charge capture templates with the correct ICD-10 pairings.
Diabetic autonomic neuropathy billing should use the E10.4x or E11.4x series — not a generic diabetes code like E11.9. The specificity matters. A claim denial on autonomic testing is often not about the CPT code — it's about a mismatched or under-specified diagnosis code.

3. Build a documentation checklist for each covered indication.
"Recurrent, unexplained syncope" requires both of those words in the chart. "Long-COVID with suspected autonomic disorder" needs a documented COVID history and a clinical rationale for autonomic involvement. Your providers need to know what language Aetna's reviewers are looking for.

4. Verify prior authorization requirements at the plan level before September 26, 2025.
The coverage policy doesn't mandate prior authorization universally. But individual Aetna plan contracts may. Call the payer for any plan product you're billing and ask directly. Document the reference number.

5. Train your scheduling and intake team on the 11 covered indications.
If a patient is scheduled for autonomic testing and their primary diagnosis doesn't map to one of Aetna's 11 indications, flag it before the appointment — not after the test runs. A test that doesn't meet medical necessity criteria won't get covered regardless of how well it's billed.

6. Confirm Long-COVID coding under your Aetna contracts.
ICD-10-CM code U09.9 (Post-COVID-19 condition, unspecified) is the most commonly used code for Long-COVID billing. But Aetna's plan-level contract may have specific language around COVID-related coding. Confirm this with your billing consultant or compliance officer before billing Long-COVID autonomic testing at scale.

CPT, HCPCS, and ICD-10 Codes for Autonomic Testing Under CPB 0485

Covered CPT Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The full ICD-10 code set under CPB 0485 includes 148 codes. Below are the primary codes your billing team will encounter most often. Work through your full payer contract to confirm the complete approved list.

The full ICD-10-CM code list under CPB 0485 includes 148 codes total. Review the complete policy at app.payerpolicy.org/p/aetna/0485 for the full code set.

A Note on the Long-COVID Indication

The Long-COVID addition deserves its own moment. This is Aetna putting a stake in the ground on post-COVID dysautonomia — a condition that has generated enormous claim volume and enormous denial volume since 2022.

The real issue for billing teams isn't whether Aetna now covers it. They do. The issue is documentation specificity. "Long-COVID" alone isn't enough. The policy language says "Long-COVID syndrome with suspected autonomic disorder." Your provider's notes need to establish both the COVID history and the clinical basis for suspecting autonomic dysfunction.

If your practice sees a high volume of post-COVID patients referred for QSART or thermoregulatory sweat testing, build a specific documentation template now. Don't wait for the first denial to figure out what Aetna's reviewers want to see.